Phaseline

Companies › LucasBio

LucasBio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB-DTK-COV19
allogeneic SARS-CoV-2-specific T cell therapy
–Phase 1COVID-19; BKV InfectionJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07709637LB-DTK-COV19Phase 1COVID-19Infectious diseaseOct 2026
NCT07670468LB-DTK-COV19Phase 1BKV InfectionInfectious diseaseJun 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.